Ascentage: Partnership With Takeda Going Well Jan 14, 2026 Bloomberg: The China Show FDA grants IND clearance to novel BTK degrader Jan 12, 2026 Drug Discovery World Significant New Treatment Options Emerge for Patients With CLL Dec 18, 2025 Hematology Advisor High-value oncology deals drive China’s drug licensing boom Dec 16, 2025 Pharmaceutical Technology Phase 3 Trial of Olverembatinib Cleared By FDA, EMA in Ph+ ALL Dec 13, 2025 Targeted Oncology ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies Dec 09, 2025 BiotechTV Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL Dec 06, 2025 Targeted Oncology Ascentage, Aiming for Regulatory Approval, Launches Global Stage of BCR-ABL Inhibitor Trial for ALL Dec 05, 2025 Precision Medicine Online The Role of Third-Generation TKIs in Overcoming Chronic Myeloid Leukemia Resistance Sep 17, 2025 Health & Pharma Ascentage Pharma’s Lisaftoclax Enters Phase III Trial for Myelodysplastic Syndrome Aug 19, 2025 Clinical Trial Vanguard
ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies Dec 09, 2025 BiotechTV
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL Dec 06, 2025 Targeted Oncology
Ascentage, Aiming for Regulatory Approval, Launches Global Stage of BCR-ABL Inhibitor Trial for ALL Dec 05, 2025 Precision Medicine Online
The Role of Third-Generation TKIs in Overcoming Chronic Myeloid Leukemia Resistance Sep 17, 2025 Health & Pharma
Ascentage Pharma’s Lisaftoclax Enters Phase III Trial for Myelodysplastic Syndrome Aug 19, 2025 Clinical Trial Vanguard
